MX9304675A - Composicion farmaceutica solida en forma de dosis, que tiene un perfil de liberacion extendido, de dos etapas y proceso para su preparacion. - Google Patents

Composicion farmaceutica solida en forma de dosis, que tiene un perfil de liberacion extendido, de dos etapas y proceso para su preparacion.

Info

Publication number
MX9304675A
MX9304675A MX9304675A MX9304675A MX9304675A MX 9304675 A MX9304675 A MX 9304675A MX 9304675 A MX9304675 A MX 9304675A MX 9304675 A MX9304675 A MX 9304675A MX 9304675 A MX9304675 A MX 9304675A
Authority
MX
Mexico
Prior art keywords
dosage form
release profile
solid pharmaceutical
stages
preparation
Prior art date
Application number
MX9304675A
Other languages
English (en)
Inventor
Eberhard Nurnberg
Erhard Seiller
Stefan Ritsert
Original Assignee
Merz & Co Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz & Co Gmbh & Co filed Critical Merz & Co Gmbh & Co
Publication of MX9304675A publication Critical patent/MX9304675A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona composiciones farmacéuticas sólidas en forma de dosis, que contienen un ingrediente o principio activo, preferentemente memantina, las cuales muestran un perfil prolongado de liberación de dos fases, y las cuales están caracterizadas por la presencia de sal de caseína ya sea soluble en agua y una insoluble en agua, preferentemente caseinato de sodio y de calcio, en la cantidad total entre 5 y 98 por ciento en peso de la composición, y con un proceso para la producción del mismo.
MX9304675A 1992-08-04 1993-08-03 Composicion farmaceutica solida en forma de dosis, que tiene un perfil de liberacion extendido, de dos etapas y proceso para su preparacion. MX9304675A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4225730A DE4225730C2 (de) 1992-08-04 1992-08-04 Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung

Publications (1)

Publication Number Publication Date
MX9304675A true MX9304675A (es) 1994-03-31

Family

ID=6464804

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304675A MX9304675A (es) 1992-08-04 1993-08-03 Composicion farmaceutica solida en forma de dosis, que tiene un perfil de liberacion extendido, de dos etapas y proceso para su preparacion.

Country Status (17)

Country Link
US (1) US5382601A (es)
EP (1) EP0582186B1 (es)
JP (1) JP3560244B2 (es)
CN (1) CN1086708A (es)
AT (1) ATE176866T1 (es)
AU (1) AU669731B2 (es)
CA (1) CA2141691C (es)
DE (2) DE4225730C2 (es)
DK (1) DK0582186T3 (es)
ES (1) ES2128369T3 (es)
GR (1) GR3030227T3 (es)
IL (1) IL106580A (es)
LT (1) LT3201B (es)
LV (1) LV10182B (es)
MX (1) MX9304675A (es)
WO (1) WO1994003158A1 (es)
ZA (1) ZA935614B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6139872A (en) * 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
AU3860797A (en) * 1997-07-16 1999-02-10 Antrin Research Limited Pharmaceutical formulations for oral administration
US5840334A (en) * 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
US5980941A (en) * 1997-08-20 1999-11-09 Fuisz Technologies Ltd. Self-binding shearform compositions
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
DE19809242A1 (de) * 1998-03-05 1999-09-09 Basf Ag Verfahren zur Herstellung von festen, sphärischen Formkörpern, enthaltend pharmazeutische Wirkstoffe in einer Bindemittelmatrix
DE19814257A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Brauseformulierungen
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
EP1852113A3 (en) * 2000-12-07 2008-03-12 Neuromolecular Inc. Methods for treating neuropsychiatric disorders with NMDA receptors antagonists
CA2554959A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
AU2005215775B2 (en) * 2004-02-13 2011-02-03 Neuromolecular, Inc. Combination of a NMDA receptor antagonist and an anti-depressive drug MAO-inhibitor or a GADPH-inhibitor for the treatment of psychiatric conditions
AU2005215767A1 (en) * 2004-02-13 2005-09-01 Adamas Pharmaceuticals, Inc. Combination of an NMDA receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other CNS disorders
CA2568445C (en) 2004-06-17 2011-05-24 Merz Pharma Gmbh & Co. Kgaa Immediate release formulations of memantine oral dosage forms
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US8039009B2 (en) * 2004-06-17 2011-10-18 Forest Laboratories Holdings Limited Modified release formulations of memantine oral dosage forms
KR100901927B1 (ko) * 2004-06-17 2009-06-10 메르츠 파마 게엠베하 운트 코. 카가아 메만타인 또는 네라멕산의 직접 압축으로 제조된 마실수 있는 즉시 방출형 제제
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
AU2005309601A1 (en) 2004-11-23 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising a sustained release coating or matrix and an NMDA receptor antagonist, method for administration such NMDA antagonist to a subject
EP1845968A2 (en) 2004-11-24 2007-10-24 Neuromolecular Pharmaceuticals, Inc Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
WO2006070930A1 (en) * 2004-12-27 2006-07-06 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
EP1874282B1 (en) 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
EP1878444B1 (en) * 2005-04-28 2015-09-09 Eisai R&D Management Co., Ltd. Composition containing anti-dementia drug
WO2006119329A2 (en) * 2005-05-02 2006-11-09 Combinatorx, Incorporated Compositions and methods for the treatment of neurodegenerative diseases
JP2008543845A (ja) * 2005-06-16 2008-12-04 フォーレスト ラボラトリーズ， インコーポレイテッド 放出調節および即放性メマンチンビーズ製剤
WO2007071257A1 (en) * 2005-12-23 2007-06-28 Alk-Abelló A/S Method for dissolution testing of pharmaceutical products
WO2008005534A2 (en) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Orally dissolving formulations of memantine
US7624743B2 (en) * 2006-09-14 2009-12-01 Halliburton Energy Services, Inc. Methods and compositions for thermally treating a conduit used for hydrocarbon production or transmission to help remove paraffin wax buildup
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
EP2583669A1 (en) 2007-10-10 2013-04-24 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
EP2363119A1 (fr) * 2010-03-05 2011-09-07 Centre Hospitalier Universitaire d'Angers Nouvelle composition pharmaceutique utile pour le traitement des personnes affectées par des maladies neurodégénératives ou neurovasculaires
US20140004189A1 (en) 2011-01-25 2014-01-02 Cadila Healthcare Limited Modified release pharmaceutical compositions memantine
EP2675435A1 (en) 2011-02-17 2013-12-25 Lupin Limited Sustained release composition of memantine
TR201104108A2 (tr) 2011-04-27 2011-08-22 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salımlı memantin tablet.
FR2980973B1 (fr) * 2011-10-11 2013-11-15 Univ Clermont Auvergne Composition pour le traitement prophylactique de la douleur neuropathique.
US20130274342A1 (en) * 2012-04-12 2013-10-17 Cerecor, Inc. Compositions and methods for treating cough
US20140050784A1 (en) 2012-08-16 2014-02-20 Teva Pharmaceuticals Usa, Inc. Pharmaceutical compositions of memantine
JP2016507542A (ja) * 2013-02-08 2016-03-10 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 反応型噴霧乾燥による無機／有機複合材料の製造
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
MX2020002078A (es) 2017-08-24 2020-09-21 Adamas Pharma Llc Composiciones de amantadina, preparaciones de estas y métodos de uso.
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US11602507B2 (en) 2019-05-27 2023-03-14 Trikona Pharmaceuticals Pvt. Ltd Extended release oral composition of memantine or its salt and its process for the preparation
CU24720B1 (es) 2020-11-24 2024-10-09 Centro De Neurociencias De Cuba Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB715874A (en) * 1952-10-03 1954-09-22 Horlicks Ltd A tablet for use in treating peptic ulcers
GB840091A (en) * 1955-09-08 1960-07-06 Upjohn Co Improvements in or relating to therapeutic compositions and the manufacture thereof
US3594467A (en) * 1968-10-09 1971-07-20 Richardson Merrell Inc Long-lasting troche
NL7305644A (es) * 1972-04-20 1973-10-23
US4076846A (en) * 1974-11-22 1978-02-28 Sumitomo Bakelite Company Limited Protein-starch binary molding composition and shaped articles obtained therefor
US4127650A (en) * 1975-03-31 1978-11-28 William H. Rorer, Inc. Medicinal simethicone containing composition and its method of production
US4419369A (en) * 1980-09-22 1983-12-06 Baylor College Of Medicine Protein mineral dietary module
US4346112A (en) * 1981-06-29 1982-08-24 University Patents Inc. Composition and method for treating patients having Parkinson's Disease
JPS59101423A (ja) * 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
AU593821B2 (en) * 1985-08-06 1990-02-22 Excel Technologies International Corporation Treating agent for liquid media
US4897380A (en) * 1985-08-30 1990-01-30 Pollack Robert L Method and composition for relieving dietary-related disorders
US4853377A (en) * 1985-10-15 1989-08-01 Pollack Robert L Method and composition for increasing production of serotonin
DK179687D0 (da) * 1987-04-08 1987-04-08 Farma Food As Praeparat
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
DE58905637D1 (de) * 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
CA2071867A1 (en) * 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
GB9004950D0 (en) * 1990-03-06 1990-05-02 Kelco Int Ltd Controlled release formulation
WO1991017745A1 (en) * 1990-05-23 1991-11-28 Southwest Research Institute Filament system for delivering a medicament and method
FR2664499B1 (fr) * 1990-07-16 1994-11-04 Jacques Dubois Nouvelles formes pharmaceutiques, leur procede de preparation et leurs applications.

Also Published As

Publication number Publication date
DE4225730C2 (de) 2003-04-30
LT3201B (en) 1995-03-27
US5382601A (en) 1995-01-17
DE4225730A1 (de) 1994-02-10
AU4706993A (en) 1994-03-03
AU669731B2 (en) 1996-06-20
GR3030227T3 (en) 1999-08-31
JPH07509479A (ja) 1995-10-19
LTIP839A (lt) 1994-08-25
LV10182A (lv) 1994-10-20
EP0582186B1 (de) 1999-02-24
ZA935614B (en) 1995-02-03
JP3560244B2 (ja) 2004-09-02
EP0582186A1 (de) 1994-02-09
DK0582186T3 (da) 1999-09-27
IL106580A0 (en) 1993-12-08
DE59309388D1 (de) 1999-04-01
WO1994003158A1 (en) 1994-02-17
CA2141691C (en) 2002-04-09
CA2141691A1 (en) 1994-02-17
IL106580A (en) 1998-02-08
ATE176866T1 (de) 1999-03-15
ES2128369T3 (es) 1999-05-16
LV10182B (en) 1995-04-20
CN1086708A (zh) 1994-05-18

Similar Documents

Publication Publication Date Title
MX9304675A (es) Composicion farmaceutica solida en forma de dosis, que tiene un perfil de liberacion extendido, de dos etapas y proceso para su preparacion.
CO4340618A1 (es) Composicion farmaceutica para liberacion controlada
GR900100481A (el) Μέ?οδος παρακευής υδατικού αιωρήματος για ουσιαστικά αδιάλυτους στο νερό ενεργούς παράγοντες.
AR033688A1 (es) Composicion parenteral reconstituible
ES2187822T3 (es) Comprimidos de disgregacion rapida.
ES2076935T3 (es) Compuesto de pirazolopiridina y procedimientos para su preparacion.
CO4600739A1 (es) Formulaciones liquidas orales a base de alendronato
MX9302609A (es) Agente sinergico y procedimiento para la lucha selectiva contra-malezas.
ES541521A0 (es) Un procedimiento para la preparacion de piridazinaminas.
HRP20010243B1 (hr) Pripravci koji sadrže difosfonske kiseline
ES2028430T3 (es) Preparaciones efervescentes de ibuprofen.
ES2180738T3 (es) Preparaciones solidas de productos activos.
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
BR9911160A (pt) Ciclosporinas
MX174336B (es) Composiciones que contienen l-tartrato de l-carnitina y procedimiento para su preparacion
AR036813A1 (es) Composiciones farmaceuticas
ES8403316A1 (es) Un procedimiento para la preparacion de una composicion a base de sales de cinc y sales de fluoruro.
AR018862A1 (es) Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion
MX9305535A (es) Composiciones y concentrados germicidas a base de yodo-detergente, acuosos y estables.
ES2178896T3 (es) Nueva forma de sal de pantoprazol.
ES2098920T3 (es) Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina.
ES2142432T3 (es) Forma de dosificacion de la gepirona.
AR021806A1 (es) COMPOSICIoN FARMACÉUTICA EN FORMA DE TABLETA QUE COMPRENDE ENTACAPONA Y MÉTODO DE PREPARACIoN.
BR9916887A (pt) Uso de derivados de pirimidina
TW372193B (en) Novel pharmaceutical composition for the preparation of a stable powder containing an association of acetylsalicylic acid and metoclopramide as the active ingredient